Recombinant Human Neutrophil Activating Peptide 2 /CXCL7 (CRP08108)
|Recombinant Human Neutrophil Activating Peptide 2 /CXCL7
- Product Overview
- Recombinant Human NAP-2/CXCL7 produced in E. coli is a single, non-glycosylated polypeptide chain containing 70 amino acids and having a molecular mass of 7.6 kDa.
- Fully biologically active when compared to standard. Determined by its ability to chemoattract human neutrophils using a concentration range of 1.0-10.0 ng/ml.
- Less than 1EU/mg of rHuNAP-2/CXCL7 as determined by LAL method.
- >97% by SDS-PAGE and HPLC analyses.
- This lyophilized preparation is stable for several weeks at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.
- We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.
PDB rendering based on 1f9pAvailable structures: 1f9p, 1nap, 1tvx
- Antigen Description
- Neutrophil Activating Peptide 2 (NAP-2) is proteolytically processed carboxyl-terminal fragments of platelet basic protein (PBP) which is found in the alpha-granules of human platelets. NAP-2 is a member of the CXC chemokines. Similar to other ELR domain containing CXC chemokines such as IL-8 and the GRO proteins, NAP-2 has been shown to bind CXCR-2 and to chemoattract and activate neutrophils. Although CTAP-III, β-TG and PBP represent amino-terminal extended variants of NAP-2 and possess the same CXC chemokine domains, these proteins do not exhibit NAP-2 activity. Recently, it has been shown that the additional amino-terminal residues of CTAP-III masks the critical ELR receptor binding domain that is exposed on NAP-2 and may account for lack of NAP-2 activity.
- chemokine activity;glucose transmembrane transporter activity;growth factor activity.
- PBP; TC1; TC2; TGB; LDGF; MDGF; TGB1; B-TG1; CTAP3; CXCL7; NAP-2; SCYB7; THBGB; LA-PF4; THBGB1; Beta-TG; CTAPIII; NAP-2-L1; TGB1;SCYB7; CXCL7_HUMAN; Platelet basic protein [Precursor]; C-X-C motif chemokine 7;Small-inducible cytokine B7;Leukocyte-derived growth factor;LDGF;Macrophage-derived growth factor;MDGF.
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.